NEW YORK, June 18, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or the "Company") today announced that the Company has entered into a definitive agreement to sell its 51% interest in Suzhou Erye Pharmaceutical Co. Ltd. ("Erye"), a China-based generic pharmaceutical company, for $12,280,000 in cash and the return to the Company of (i) 1,040,000 shares of the Company's Common Stock and (ii) the cancellation of 1,170,000 options and 640,000 Common Stock warrants, which collectively represent 1.3% of the Company's fully diluted issued and outstanding shares. The closing of the transaction is subject to the approval of NeoStem shareholders and certain other conditions. Closing of the transaction is expected to occur by the fourth quarter of 2012.
"We are pleased to have reached this significant milestone in our business," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. "This divestiture will enable NeoStem to bolster its cash position in the United States, reduce its legal and financial reporting expenditures, simplify its financials and become a pure play in the rapidly growing cell therapy industry. Consummation of the transaction will also eliminate significant Erye debt from the Company's balance sheet, which was over $37 million as of March 31, 2012."
NeoStem acquired its interest in Erye in October 2009 and was heralded, at that time, for its innovative business move into the emerging Chinese pharmaceutical industry. In 2011, the Chinese government imposed new policies affecting price and volume controls of certain pharmaceutical products, including generic antibiotics, which reduced the division's profitability and positive cash flows. This dampened Erye's operating results and was the catalyst for NeoStem to begin to evaluate opportunities to monetize its interest in Erye.
The divestiture will enable NeoStem to focus full time on its goal to emerge as a leader in the cell therapy market. The Company is enrolling patients in its PreSERVE AMR-001 Phase 2 clinical trial for preserving heart function after a heart attack and expanding its cell therapeutic contract manufacturing business, PCT. NeoStem also plans to continue to develop and to build on its core capabilities in cell therapy to capitalize on the paradigm shift that is occurring in medicine.
Over one million people in the Unites States suffer a heart attack annually. One in five people who survive a heart attack dies within a year. Of those individuals that do live, many of them have worsening heart function over time. NeoStem's Phase 2 therapeutic product candidate, AMR-001, takes stem cells from a person's own body and injects them one time into the heart through the infarct related artery in order to lay down new blood vessels, with the intent of preserving heart function. Management remains focused on the key objective of completing enrollment of the PreSERVE AMR-001 Phase 2 clinical trial in order to have data during the second half of 2013.
About NeoStem, Inc.
NeoStem, Inc. ("we," "NeoStem" or the "Company") continues to develop and build on its core capabilities in cell therapy to capitalize on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. Our January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") provides NeoStem with a foundation in both manufacturing and regulatory affairs expertise. We believe this expertise, coupled with our existing research capabilities and collaborations, will allow us to achieve our mission of becoming a premier cell therapy company. Our PCT subsidiary's manufacturing base is one of the few current Good Manufacturing Practices ("cGMP") facilities available for contracting in the burgeoning cell therapy industry. Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and Amorcyte is enrolling patients for a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. We also expect to begin a Phase 1 clinical trial by 2012/2013 to investigate AMR-001's utility in arresting the progression of congestive heart failure and the associated comorbidities of that disease. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is engaged in collaboration with Becton-Dickinson that is exploring the earlier stage clinical development of a T-cell therapy for autoimmune conditions. In addition, our pre-clinical assets include our VSELTM Technology platform as well as our MSC (mesenchymal stem cells) product candidate for regenerative medicine.
For more information on NeoStem, please visit http://www.neostem.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to whether the Erye divestiture will close successfully and the successful execution of the Company's business and medical strategy in general, including with respect to the development of AMR-001 and other cell therapies about which no assurance can be given. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
Read more:
NeoStem Signs a Definitive Agreement to Divest Its 51% Ownership Interest in Suzhou Erye
- More Stem Cells Extracted For Later Use For My MS - March 14th, 2011 [March 14th, 2011]
- Stem Cell Institute Panama City Panama - April 1st, 2011 [April 1st, 2011]
- Cells That Heal Us From Cradle To Grave: A Quantum Leap in Medical Science - April 8th, 2011 [April 8th, 2011]
- Macular Degeneration Improved With Stem Cells - April 8th, 2011 [April 8th, 2011]
- Stem Cell Therapy for Kidney Failure - April 15th, 2011 [April 15th, 2011]
- SIRA: Could Stem Cell Therapy Renew Your Body Cells? - April 22nd, 2011 [April 22nd, 2011]
- Stem Cell Therapy for Autism - May 20th, 2011 [May 20th, 2011]
- Stem Cell Therapy for Critical Limb Ischemia - May 21st, 2011 [May 21st, 2011]
- STEM CELLS FOR MACULAR DEGENERATION Sam Smith's story.wmv - May 21st, 2011 [May 21st, 2011]
- Stem Cell Therapy Success - May 21st, 2011 [May 21st, 2011]
- Doctors Use Stem Cells to Grow New Windpipes - May 21st, 2011 [May 21st, 2011]
- Dog Undergoes Stem Cell Therapy - May 23rd, 2011 [May 23rd, 2011]
- Stem Cell Therapy for Multiple Sclerosis - May 23rd, 2011 [May 23rd, 2011]
- Dogs now getting stem cell therapy - May 24th, 2011 [May 24th, 2011]
- Stem Cell Therapy for Rheumatoid Arthritis - May 30th, 2011 [May 30th, 2011]
- Stem Cell Therapy for Type II Diabetes - May 31st, 2011 [May 31st, 2011]
- Stem Cell Therapy for Cerebral Palsy - May 31st, 2011 [May 31st, 2011]
- Visions Episode 92: Stem Cells Discovery - May 31st, 2011 [May 31st, 2011]
- Stem Cell Therapy For Alzheimer's/Dementia - June 1st, 2011 [June 1st, 2011]
- Stem Cell Patient Richard H. MS Treatment - June 10th, 2011 [June 10th, 2011]
- Stem Cell Therapy Injections - June 12th, 2011 [June 12th, 2011]
- Stem Cells Used to Grow Windpipes - June 20th, 2011 [June 20th, 2011]
- Stem Cell Therapy for Stroke - Gary Steinberg, Stanford University - June 21st, 2011 [June 21st, 2011]
- Lou Gehrig's Disease (ALS): UCSD Team's Stem Cell Therapy Approach - June 23rd, 2011 [June 23rd, 2011]
- Stem Cell Therapy Cream: Less Wrinkles In 30 Days or Less Anti-Wrinkle Cream That Works - June 26th, 2011 [June 26th, 2011]
- Stem Cell Therapy for Spinal Cord Injury - Injured Airline Pilot Flies Again - June 27th, 2011 [June 27th, 2011]
- Clinical Advances in Adult Stem Cell Therapy: Dr. Jorge Paz - June 27th, 2011 [June 27th, 2011]
- Stem Cell Injection Treatment - Stem Cell Therapy - June 27th, 2011 [June 27th, 2011]
- Stem Cell Therapy MS: Sam Harrell and The Superbowl - June 27th, 2011 [June 27th, 2011]
- Documentary: Stem Cell Therapy for Muscular Dystrophy - Ryan Benton's Story - June 30th, 2011 [June 30th, 2011]
- Stem Cell Therapy--Hillcrest Animal Hospital - July 14th, 2011 [July 14th, 2011]
- WAVE3 News Adipose Stem Cell Therapy - July 20th, 2011 [July 20th, 2011]
- Lou Gehrig's Disease (ALS): Stem Cell Therapy - A Patient's Perspective - July 23rd, 2011 [July 23rd, 2011]
- University of Melbourne announce Stem Cells Discovery - July 28th, 2011 [July 28th, 2011]
- Stem Cell Therapy (Regenerative Medicine) in New Jersey - August 9th, 2011 [August 9th, 2011]
- Spinal Cord Injury - Stem Cell Therapy - August 9th, 2011 [August 9th, 2011]
- Dr. Craig Saunders Adult Stem Cell Therapy - August 9th, 2011 [August 9th, 2011]
- Embryonic stem cell therapy in China (www.esctherapy.com) - August 13th, 2011 [August 13th, 2011]
- Mesenchymal stem cells and marrow stromal cells - August 15th, 2011 [August 15th, 2011]
- Mesenchymal Stem Cells in Regenerative Medicine: Of Hopes and Challenges - August 15th, 2011 [August 15th, 2011]
- Cardiomyogenic differentiation of Mesenchymal Stem cells (KUM2/9-15c) - August 15th, 2011 [August 15th, 2011]
- SENS4 - Engineered Mesenchymal Stem Cells - The Road to Skeletal Tissue Regeneration (1/3) - August 15th, 2011 [August 15th, 2011]
- Mesenchymal stem cells and marrow stromal cells---2nd--- - August 15th, 2011 [August 15th, 2011]
- Cadiomyogenesis of human mesenchymal stem cells - August 15th, 2011 [August 15th, 2011]
- Mesenchymal Stem Cells Transplantation In Heart.wmv - August 15th, 2011 [August 15th, 2011]
- Ying Liu discusses IPS cell therapy for ALS - August 15th, 2011 [August 15th, 2011]
- Non-controversial Stem Cells: Rationale for Clinical Use: Neil Riordan, Ph.D. - Miami, FL - August 16th, 2011 [August 16th, 2011]
- From Surgical Repair to Stem Cell Repair: A Surgeon's Journey by Leonard Smith MD, FACS - August 16th, 2011 [August 16th, 2011]
- Bone Marrow Aspiration - Stem Cell Therapy - August 16th, 2011 [August 16th, 2011]
- Non-controversial Stem Cells: Rationale for Clinical Use - Dr. Neil Riordan - August 16th, 2011 [August 16th, 2011]
- TEDxSingapore - Susan Lim - Hype and hope of stem cell research - August 16th, 2011 [August 16th, 2011]
- Cryo-Lip Instruction Video.VOB.flv - August 16th, 2011 [August 16th, 2011]
- Stem Cells Repair Damaged Heart [7-07-2011] - August 16th, 2011 [August 16th, 2011]
- Andalusian Stem Cell Bank - August 16th, 2011 [August 16th, 2011]
- Adult Stem Cell Therapy Clinical Advances - Dr. Jorge Paz in San Diego, CA March 2011 - August 16th, 2011 [August 16th, 2011]
- Mesenchymal Stem Cells Drive New MS Study/Treatment - August 26th, 2011 [August 26th, 2011]
- Sims 2 Mafia Story Part 7 - Farewell, Godfather/Stem Cell Medicine - August 28th, 2011 [August 28th, 2011]
- STEM CELLS - Mesenchymal Stem Cells (Balzitt).flv - August 30th, 2011 [August 30th, 2011]
- Regenerative Medicine With Stem Cell Therapy Injections at an Arizona pain clinic (602) 507-6550 - September 3rd, 2011 [September 3rd, 2011]
- Stem Cell Research: Huntington's Disease - September 5th, 2011 [September 5th, 2011]
- Autism Stem Cell Trip - September 6th, 2011 [September 6th, 2011]
- Before/After Stem Cell for COPD: From Unable to Walk, to Dancing at My Daughter's Wedding - September 6th, 2011 [September 6th, 2011]
- Regenerative Medicine with Placenta Extracts and Stem Cell Therapies - Dr. Janethy Balakrishnan - September 6th, 2011 [September 6th, 2011]
- Stem Cells - September 6th, 2011 [September 6th, 2011]
- The Politics and Promise of Stem Cell Research - September 6th, 2011 [September 6th, 2011]
- Stem cell therapy in Guatemala - (closer than China) - September 7th, 2011 [September 7th, 2011]
- Stem Cell Therapy for Cerebral Palsy - Holly Catalano - September 9th, 2011 [September 9th, 2011]
- Clinical Advances in Adult Stem Cell Therapy - Dr. Jorge Paz Rodriguez (Miami) - September 9th, 2011 [September 9th, 2011]
- CryoLip Stem Cell Preservation - September 20th, 2011 [September 20th, 2011]
- Dr. Gonzalez tells his story of Stem Cell Treatment and Stem Cell Therapy - September 23rd, 2011 [September 23rd, 2011]
- A Three Minute Cell Passage - September 23rd, 2011 [September 23rd, 2011]
- Bone Marrow - Stem Cell Prolotherapy - September 23rd, 2011 [September 23rd, 2011]
- Stem Cell Therapy- Interview with Indian Surgeon - September 23rd, 2011 [September 23rd, 2011]
- Cryo-Lip.f4v - September 23rd, 2011 [September 23rd, 2011]
- CryoCord Corporate Video (2 Mins) - September 23rd, 2011 [September 23rd, 2011]
- SENS4 - Engineered Mesenchymal Stem Cells - The Road to Skeletal Tissue Regeneration (3/3) - September 23rd, 2011 [September 23rd, 2011]
- What are stem cells? - September 24th, 2011 [September 24th, 2011]
- Dental stem cell bank in Hyderabad - September 24th, 2011 [September 24th, 2011]
- Stem Cell Therapeutics: Tissue Regeneration - Christopher J. Centeno, MD - September 25th, 2011 [September 25th, 2011]
- Stem Cell Types and Sources - September 25th, 2011 [September 25th, 2011]